Abbott and Flatiron Health announced the integration of Abbott’s full Precision Oncology test portfolio into Flatiron’s cloud-based OncoEMR platform. This move allows oncologists across more than 1,600 community cancer centers to order tests digitally and receive results directly within their existing clinical workflow.
Glimpse:
The collaboration expands access to advanced genomic and molecular tests for thousands of providers treating cancer patients in community settings. By embedding Abbott’s tests into OncoEMR, the integration reduces administrative hurdles, speeds up decision-making, and supports more personalized treatment approaches without disrupting daily practice.
Abbott has partnered with Flatiron Health to bring its comprehensive Precision Oncology portfolio directly into one of the most widely used oncology electronic medical record systems in the United States. Announced on March 30, 2026, the integration enables oncology providers to order Abbott’s specialized cancer tests either individually or in panels and track their status and results seamlessly within Flatiron’s OncoEMR platform.
This development significantly improves workflow efficiency for clinicians working in community cancer care settings. Previously, ordering advanced molecular tests often involved separate systems or manual processes that could delay treatment decisions. Now, with the tests embedded in the familiar OncoEMR environment, providers can make faster, more informed choices based on precise tumor profiling, ultimately helping tailor therapies to individual patients.
The integration covers Flatiron Health’s extensive national network, which includes over 1,600 community cancer care centers and more than 4,700 providers. This broad reach is particularly important because a large portion of cancer patients in the US receive care outside major academic hospitals. By making sophisticated precision oncology tools more accessible at the point of care, the partnership aims to bridge the gap between advanced diagnostics and routine clinical practice.
Abbott’s Precision Oncology offerings include genomic assays designed to guide treatment decisions across various cancer types. The seamless connection with OncoEMR is expected to reduce friction in test ordering, minimize errors, and accelerate the delivery of results to physicians. Both companies view this as a step toward more efficient, patient-centered cancer care that leverages technology to support better outcomes.
This initiative reflects the growing emphasis on precision medicine in oncology, where detailed molecular insights play a critical role in selecting targeted therapies and improving survival rates. As community oncology practices adopt such integrated solutions, more patients stand to benefit from personalized approaches without needing referrals to specialized centers.
“By integrating Abbott’s Precision Oncology portfolio directly into OncoEMR, we’re reducing friction in the workflow and helping providers move quickly from diagnosis to targeted treatment”
By
HB Team
Related News
